Newsfeeds Archive - Page 2 of 3

2 minute read

Atossa Therapeutics Provides Enrollment Update For Ongoing Phase 2 Karisma-Endoxifen Clinical Trial; 170 Patients Have Been Enrolled In The Company’s Ongoing Phase 2 Karisma-Endoxifen Clinical Trial. Atossa Expects The Study To Fully Enroll In Q4 2023

July 10, 9:16 AM

Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced

ATOS

2 minute read

News

Atossa Therapeutics Granted Additional Patent Protection For Endoxifen

By Happy Mohamed

June 21, 10:15 AM

Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today

ATOS

3 minute read

Atossa Completes Enrollment Of Pharmacokinetic Run-In Cohort In Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen As A Neoadjuvant Treatment For ER+ / HER2- Breast Cancer

By Benzinga Newsdesk

June 12, 9:16 AM

ATOS

3 minute read

Atossa Therapeutics Further Strengthens Intellectual Property Portfolio With Additional Broad Patent For Endoxifen

By Happy Mohamed

February 13, 10:17 AM

Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet need in cancer, today announces that the United States Patent

ATOS

16 minute read

Options

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

December 28, 12:23 PM

On Wednesday, 258 companies hit new 52-week lows.

ACB

14 minute read

Options

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

December 15, 12:19 PM

On Thursday, 241 companies hit new 52-week lows.

ACHL

11 minute read

Options

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

December 6, 1:22 PM

Tuesday's session saw 167 companies set new 52-week lows.

ACHL

4 minute read

Options

Stocks That Hit 52-Week Lows On Monday

By Benzinga Insights

December 5, 12:09 PM

During Monday's session, 49 companies made new 52-week lows.

ADTH

1 minute read

Atossa Genetics Q3 EPS $(0.06) Down From $(0.04) YoY

By Benzinga Newsdesk

November 7, 5:29 PM

Atossa Genetics (NASDAQ:ATOS) reported quarterly losses of $(0.06) per share. This is a 50 percent decrease over losses of $(0.04) per share from the same period last year.

ATOS